Toronto Dominion Bank Buys 16,881 Shares of Revvity, Inc. (NYSE:RVTY)

Toronto Dominion Bank grew its stake in Revvity, Inc. (NYSE:RVTY) by 40.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 58,374 shares of the company’s stock after purchasing an additional 16,881 shares during the period. Toronto Dominion Bank’s holdings in Revvity were worth $6,515,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Assetmark Inc. grew its position in Revvity by 3,700.0% during the 4th quarter. Assetmark Inc. now owns 266 shares of the company’s stock worth $30,000 after acquiring an additional 259 shares during the last quarter. Optiver Holding B.V. bought a new stake in Revvity during the 4th quarter worth approximately $33,000. Quarry LP grew its position in Revvity by 45.7% during the 4th quarter. Quarry LP now owns 303 shares of the company’s stock worth $34,000 after acquiring an additional 95 shares during the last quarter. Millstone Evans Group LLC acquired a new position in Revvity during the 4th quarter worth $38,000. Finally, Continuum Advisory LLC lifted its holdings in Revvity by 39.3% during the 4th quarter. Continuum Advisory LLC now owns 471 shares of the company’s stock worth $53,000 after buying an additional 133 shares in the last quarter. 86.65% of the stock is currently owned by institutional investors.

Revvity Stock Performance

RVTY stock opened at $91.82 on Friday. The business’s fifty day moving average is $95.35 and its 200-day moving average is $108.44. The company has a quick ratio of 3.03, a current ratio of 3.60 and a debt-to-equity ratio of 0.41. The company has a market cap of $10.82 billion, a P/E ratio of 41.55, a price-to-earnings-growth ratio of 3.82 and a beta of 1.02. Revvity, Inc. has a twelve month low of $88.01 and a twelve month high of $129.50.

Revvity (NYSE:RVTY) last released its quarterly earnings data on Monday, April 28th. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. The business had revenue of $664.76 million during the quarter, compared to analysts’ expectations of $662.30 million. During the same quarter in the prior year, the company earned $0.98 EPS. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. Equities research analysts forecast that Revvity, Inc. will post 4.94 EPS for the current year.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 8th. Investors of record on Friday, July 18th will be given a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.30%. The ex-dividend date is Friday, July 18th. Revvity’s dividend payout ratio is currently 11.91%.

Analyst Ratings Changes

Several research analysts have issued reports on the company. The Goldman Sachs Group reduced their price objective on Revvity from $140.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Wells Fargo & Company reduced their price objective on Revvity from $130.00 to $102.00 and set an “equal weight” rating on the stock in a report on Thursday, April 17th. Robert W. Baird reduced their price objective on Revvity from $127.00 to $125.00 and set an “outperform” rating on the stock in a report on Tuesday, April 29th. KeyCorp upped their price objective on Revvity from $132.00 to $145.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. Finally, JPMorgan Chase & Co. reduced their price objective on Revvity from $120.00 to $100.00 and set a “neutral” rating on the stock in a report on Tuesday, April 29th. Five investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $125.64.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.